The Detrimental Course of Acute Intestinal Ischemia
Launched by MAASTRICHT UNIVERSITY · Jan 4, 2022
Trial Information
Current as of August 22, 2025
Unknown status
Keywords
ClinConnect Summary
INTRODUCTION AND RATIONALE Acute intestinal ischemia remains a common clinical emergency with short-term mortality up to 80% and is often highly underestimated. , , It is a life-threatening clinical condition of diminished blood flow towards the gut, resulting in decreased supply of oxygen and nutrients to the intestinal tissue. Prolonged periods of ischemia are associated with disruption of the intestinal wall that normally functions as an important barrier. , The intestinal wall is composed of different layers and has a multitude of functions, such as the absorption of nutrients as well a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • All consecutive patients admitted to one of the participating medical centers emergency departments (ED) or at the intensive care unit (ICU) (see 4.1 Population Base) with clinical suspicion of acute intestinal ischemia, which is based on;
- • clinical manifestation;
- • physical examination by the physician;
- • laboratory measurements;
- • physician's consideration to perform computed tomography (CT)-scan
- Exclusion Criteria:
- A subject who meets any of the following criteria will be excluded from participation in this study:
- • Age ≤ 18 years In order to evaluate the performance of the panel of markers for the acute intestinal ischemia in clinical practice, the study population must resemble the clinical patient population as closely as possible
About Maastricht University
Maastricht University is a leading academic institution in the Netherlands, renowned for its innovative approach to research and education in the health sciences. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials that aim to advance medical knowledge and improve patient outcomes. Maastricht University leverages its state-of-the-art facilities and expertise in various fields, including biomedical research, public health, and clinical practice, to conduct high-quality clinical studies that adhere to rigorous ethical standards. Committed to translating research findings into real-world applications, the university plays a pivotal role in addressing contemporary health challenges and enhancing healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Groningen, , Netherlands
Apeldoorn, Gelderland, Netherlands
Maastricht, Limburg, Netherlands
Amsterdam, Noord Holland, Netherlands
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Annet Duivenvoorden, MSc
Study Chair
Maastricht University
Kaatje Lenaerts, PhD
Principal Investigator
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials